Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB2008 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Mouse Monoclonal Kallikrein 6/Neurosin Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human Kallikrein 6/Neurosin in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human (rh) Factor X, recombinant mouse HGFA, rhKLK3, 4, 5, 8, 10, 11, 15, rhThrombin, or rhuPA is observed.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
Inhibition of transcription factor specificity protein 1 alters the gene expression profile of keratinocytes leading to upregulation of kallikrein-related peptidases and thymic stromal lymphopoietin.
Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E
Molecular neurodegeneration 2015 Sep 23;10:48
Molecular neurodegeneration 2015 Sep 23;10:48
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM
PloS one 2013;8(1):e53250
PloS one 2013;8(1):e53250
Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E
Molecular therapy : the journal of the American Society of Gene Therapy 2013 Jan;21(1):31-41
Molecular therapy : the journal of the American Society of Gene Therapy 2013 Jan;21(1):31-41
Inhibition of transcription factor specificity protein 1 alters the gene expression profile of keratinocytes leading to upregulation of kallikrein-related peptidases and thymic stromal lymphopoietin.
Bin L, Kim BE, Hall CF, Leach SM, Leung DY
The Journal of investigative dermatology 2011 Nov;131(11):2213-22
The Journal of investigative dermatology 2011 Nov;131(11):2213-22
No comments: Submit comment
No validations: Submit validation data